Corporate Connect Research analyst Marc Sinatra recently published a research report on Antisense Therapeutics (ASX:ANP) with a 30.5 cent valuation. The report is available for free download.
Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development.
In this video Marc discusses
- What’s the attraction of ANP at these levels?
- How’s the ANP valuation derived?
- What are the key drivers for valuation upside?